Despite significant advances in their molecular pathogenesis, skeletal vascular tumors remain diagnostically challenging due to their aggressive radiologic appearance and significant morphologic overlap. Within the epithelioid category and at the benign end of the spectrum, recurrent FOS/FOSB fusions have defined most epithelioid hemangiomas, distinguishing them from epithelioid hemangioendothelioma and angiosarcoma. More recently, the presence of EWSR1/FUS :: NFATC1/2 fusions emerged as the genetic hallmark of a novel group of unusual vascular proliferations, often displaying epithelioid morphology, with alternating vasoformative and solid growth, variable atypia, reminiscent of composite hemangioendothelioma. In this study, we further our understanding and morphologic spectrum of NFATC -fusion positive vascular neoplasms by describing 9 new cases, including soft tissue locations and novel fusion partners. Combining with the initial cohort of 5 cases, a total of 14 patients were analyzed, showing slight female predilection and an age range of 10 to 66 (mean 42 y). Twelve patients had solitary lesions, while 2 had multifocal polyostotic (pelvic bones) disease. Overall, 12 lesions were intra-osseous and 2 in soft tissue. By targeted RNA Fusion panels or FISH, there were 6 cases of EWSR1::NFATC1 , 4 EWSR1::NFATC2 , 2 FUS::NFATC2 , 1 EWSR1 rearrangement, and 1 with a novel FABP4::NFATC2 fusion. Follow-up was available in 4 patients. One patient experienced 2 local recurrences, 11 and 15 years postdiagnosis, and one patient experienced progressive disease despite multimodality treatment (curettings, embolization, radiation) over 3 years. In summary, our extended investigation confirms that NFATC -related fusions define a distinct group of vascular neoplasms with variable architecture, epithelioid phenotype, and cytologic atypia, commonly located in the bone, occasionally multifocal and with potential for local recurrence and aggressive behavior but no metastatic potential. Molecular analysis is recommended in diagnostically challenging cases with atypical histology to exclude malignancy.

Biopticka Laboratory Pilsen Czech Republic

Bordeaux Institute of Oncology BRIC INSERM Bordeaux University Bergonié Institute Bordeaux France

Cedars Sinai Medical Center Los Angeles CA

Department of Biopathology Institut Bergonié Comprehensive Cancer Center

Department of Pathology and Lab Medicine Memorial Sloan Kettering Cancer Center New York NY

Department of Pathology and Laboratory Medicine Dartmouth Health

Department of Pathology Charles University Faculty of Medicine in Plzen Czech Republic

Geisel School of Medicine at Dartmouth Lebanon NH

Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH

University of Pittsburgh Medical Center Shadyside Pittsburgh PA

See more in PubMed

Evans HL, Raymond AK, Ayala AG. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol. 2003;34(7):680–689. PubMed

Nielsen GP, Srivastava A, Kattapuram S, et al. Epithelioid hemangioma of bone revisited: a study of 50 cases. Am J Surg Pathol. 2009;33(2):270–277. PubMed

Errani C, Zhang L, Panicek DM, et al. Epithelioid hemangioma of bone and soft tissue: a reappraisal of a controversial entity. Clin Orthop Relat Res®. 2012;470(5):1498–1506. PubMed PMC

O’Connell JX, Kattapuram SV, Mankin HJ, et al. Epithelioid hemangioma of bone. A tumor often mistaken for low-grade angiosarcoma or malignant hemangioendothelioma. Am J Surg Pathol. 1993;17(6):610–617. PubMed

Huang S-C, Zhang L, Sung Y-S, et al. Frequent FOS gene rearrangements in epithelioid hemangioma: a molecular study of 58 cases with morphologic reappraisal. Am J Surg Pathol. 2015;39(10):1313. PubMed PMC

Antonescu CR, Chen HW, Zhang L, et al. ZFP36‐FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer. 2014;53(11):951–959. PubMed PMC

van IJzendoorn DG, de Jong D, Romagosa C, et al. Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes Cancer. 2015;54(9):565–574. PubMed

Tsuda Y, Suurmeijer AJ, Sung YS, et al. Epithelioid hemangioma of bone harboring FOS and FOSB gene rearrangements: a clinicopathologic and molecular study. Genes Chromosomes Cancer. 2021;60(1):17–25. PubMed PMC

Antonescu CR, Huang S-C, Sung Y-S, et al. Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. Mod Pathol. 2021;34(5):934–941. PubMed PMC

Errani C, Zhang L, Sung YS, et al. A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–653. PubMed PMC

Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775–784. PubMed PMC

Dermawan JK, Azzato EM, Billings SD, et al. YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases. Mod Pathol. 2021;34(12):2211–2221. PubMed

Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82-. PubMed

Dashti NK, Dickson BC, Zhang L, et al. A unique epithelioid vascular neoplasm of bone characterized by EWSR1/FUS‐NFATC1/2 fusions. Genes Chromosomes Cancer. 2021;60(11):762–771. PubMed PMC

Ong SL, Lam SW, van den Akker BE, et al. Expanding the spectrum of EWSR1-NFATC2-rearranged benign tumors: a common genomic abnormality in vascular malformation/hemangioma and simple bone cyst. Am J Surg Pathol. 2021;45(12):1669. PubMed PMC

Chung CT, Antonescu CR, Dickson BC, et al. Pediatric fibromyxoid soft tissue tumor with PLAG1 fusion: a novel entity? Genes Chromosomes Cancer. 2021;60(4):263–271. PubMed PMC

Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20(12):1479–1484. PubMed

Antonescu CR, Zhang L, Chang NE, et al. EWSR1‐POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty‐six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010;49(12):1114–1124. PubMed PMC

Tsuda Y, Zhang L, Meyers P, et al. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: impact of gene fusion type on clinical features and outcome. Genes Chromosomes Cancer. 2020;59(9):525–534. PubMed PMC

Kr Szuhai, IJszenga M, de Jong D, et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res. 2009;15(7):2259–2268. PubMed

Diaz-Perez JA, Nielsen GP, Antonescu C, et al. EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review. Hum Pathol. 2019;90(8):45–53. PubMed PMC

Bode-Lesniewska B, Fritz C, Exner GU, et al. EWSR1-NFATC2 and FUS-NFATC2 gene fusion-associated mesenchymal tumors: clinicopathologic correlation and literature review. Sarcoma. 2019;26(3):9386390 PubMed PMC

Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. Mod Pathol. 2017;30(11):1589–1602. PubMed

Antonescu CR, Dickson BC, Sung Y-S, et al. Recurrent YAP1 and MAML2 gene rearrangements in retiform and composite hemangioendothelioma. Am J Surg Pathol. 2020;44(12):1677–1684 PubMed PMC

Arbajian E, Magnusson L, Brosjö O, et al. A Benign Vascular Tumor With a New Fusion Gene: EWSR1-NFATC1: in Hemangioma of the Bone. Am J Surg Pathol. 2013;37(4):613–616. PubMed

WHO classification of tumours: soft tissue and bone tumours. 5th ed. International Agency for Research on Cancer; 2020.

Rosenbaum E, Jadeja B, Xu B, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol. 2020;33(4):591–602. PubMed PMC

Wang GY, Thomas DG, Davis JL, et al. EWSR1-NFATC2 translocation-associated sarcoma clinicopathologic findings in a rare aggressive primary bone or soft tissue tumor. Am J Surg Pathol. 2019;43(8):1112–1122. PubMed

Watson S, Perrin V, Guillemot D, et al. Transcriptomic definition of molecular subgroups of small round cell sarcomas. Journal Pathol. 2018;245(1):29–40. PubMed

Perret R, Escuriol J, Velasco V, et al. NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Mod Pathol. 2020;33(10):1930–1944. PubMed

Szuhai K, IJszenga M, Tanke HJ, et al. Detection and molecular cytogenetic characterization of a novel ring chromosome in a histological variant of Ewing sarcoma. Cancer Genet Cytogenet. 2007;172(1):12–22. PubMed

Pižem J, Šekoranja D, Zupan A, et al. FUS-NFATC2 or EWSR1-NFATC2 fusions are present in a large proportion of simple bone cysts. Am J Surg Pathol. 2020;44(12):1623–1634. PubMed

Hung YP, Fisch AS, Diaz‐Perez JA, et al. Identification of EWSR1–NFATC2 fusion in simple bone cysts. Histopathology. 2021;78(6):849–856. PubMed

Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136–142. PubMed

Rao A NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol Today. 1994;15(6):274–281. PubMed

Serfling E, Avots A, Neumann M. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta (BBA) 1995;1263(3):181–200. PubMed

Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369(6480):497–502. PubMed

Shaw K, Ho AM, Raghavan A, et al. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci. 1995;92(24):11205–11209. PubMed PMC

Hernández GL, Volpert OV, Íñiguez MA, et al. Selective inhibition of vascular endothelial growth factor–mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193(5):607–620. PubMed PMC

Armesilla AL, Lorenzo E, del Arco PG, et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol. 1999;19(3):2032–43 PubMed PMC

Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med. 2008;14(11):1236–1246. PubMed PMC

Zaichuk TA, Shroff EH, Emmanuel R, et al. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med. 2004;199(11):1513–1522. PubMed PMC

Friday BB, Pavlath GK. A calcineurin-and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells. J Cell Sci. 2001;114(2):303–310. PubMed

Horsley V, Friday BB, Matteson S, et al. Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. J Cell Biol. 2001;153(2):329–338. PubMed PMC

Wang J, Gardner BM, Lu Q, et al. Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes. J Pathol. 2009;219(2):163–172. PubMed PMC

Kim JH, Kim N. Regulation of NFATc1 in osteoclast differentiation. J Bone Metab. 2014;21(4):233–241. PubMed PMC

Ho I-C, Kim JH-J, Rooney JW, et al. A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci. 1998;95(26):15537–15541. PubMed PMC

Perotti V, Baldassari P, Molla A, et al. NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene. 2016;35(22):2862–2872. PubMed

Jauliac S, López-Rodriguez C, Shaw LM, et al. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002;4(7):540–544. PubMed

Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab. 2000;11(5):175–180. PubMed

Fagerberg L, Hallström BM, Oksvold P, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406. PubMed PMC

Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996;274(5291):1377–1379. PubMed

Zhao W, Rasheed A, Tikkanen E, et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet. 2017;49(10):1450–1457. PubMed PMC

Prentice KJ, Saksi J, Robertson LT, et al. A hormone complex of FABP4 and nucleoside kinases regulates islet function. Nature. 2021;600(7890):720–726. PubMed PMC